Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ACP1 | P24666 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.43 |
| ▸ | STK4 | Q13043 | 1/20 | 0.43 |
| ▸ | STK3 | Q13188 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | IRAK1 | P51617 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3975338 | 0.88 | ACP1 (0.56) | DHFRADORA1ADORA2AACP1CHRM3 | |
| SCHEMBL5655636 | 0.85 | DHFR (0.46) | DHFRADORA1ACP1CHRM3DRD2 | |
| SCHEMBL5654259 | 0.83 | STK4 (0.49) | DHFRADORA1ADORA2ASTK4STK3 | |
| SCHEMBL4107730 | 0.83 | IRAK1 (0.46) | DHFRADORA1ADORA2ASTK4STK3 | |
| SCHEMBL14556190 | 0.82 | DHFR (0.48) | DHFRADORA1ADORA2ACHRM3STK4 | |
| SCHEMBL14556155 | 0.82 | DHFR (0.48) | DHFRADORA1ADORA2ACHRM3STK4 | |
| SCHEMBL5656962 | 0.82 | DHFR (0.48) | DHFRADORA1ADORA2ACHRM3STK4 | |
| Hydrochloric Acid SCHEMBL4105397 | 0.82 | STK4 (0.48) | DHFRADORA1ADORA2ASTK4STK3 | |
| SCHEMBL3973670 | 0.78 | DHFR (0.48) | DHFRADORA1ADORA2ASTK4STK3 | |
| SCHEMBL4118866 | 0.78 | DHFR (0.50) | DHFRADORA1ADORA2AACP1IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293494-A1 | 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines | DJUNG JANE F | 2007-12-20 | — | — | US | claimed |
| US-8354407-B2 | 2-anilino-4-(heterocyclic)amino-pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-15 | — | — | US | disclosed |
| US-20090227586-A1 | 2-ANILINO-4-(HETEROCYCLIC)AMINO-PYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293494-A1 | 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines | PRKCA, PRKCG, PRKCH | DHFR 1013/4885ADORA1 303/4885ADORA2A 341/4885 |
| US-20090227586-A1 | 2-ANILINO-4-(HETEROCYCLIC)AMINO-PYRIMIDINES | PRKCA, PRKCG, PRKCH | DHFR 1013/4885ADORA1 303/4885ADORA2A 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.